Protocol stopping criteria (safety) were met.

The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.

Inclusion Criteria:

• Are overtly healthy male or female Japanese or non-Japanese participants, as determined by medical history and physical examination
• Women not of childbearing potential
• Are aged 18 to 55 years (20 to 55 years for Japanese participants), inclusive, at screening

Exclusion Criteria:

• Have clinically significant abnormal electrocardiogram (ECG) results
• Have persistent abnormal blood pressure or pulse rate, as determined by the investigator
• Have evidence of orthostatic hypotension, defined as a decrease in systolic or diastolic blood pressure greater than or equal to (≥)20 millimeters of mercury (mmHg) or ≥10 mmHg, respectively
• Have significant history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders
• Have a history or presence of mononeuropathy, polyneuropathy, or autonomic neuropathy
• Have significant allergies to humanized monoclonal antibodies

All randomized participants.

Baseline through study completion (up to 109 days)

All randomized participants who received at least one dose of study drug.

Cohort 2 through 7 were not explored as study was terminated early for safety reasons after Cohort 1.